Cover Image
市場調查報告書

中國的Olmesartan市場分析

Investigation Report on China Olmesartan Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 297275
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Olmesartan市場分析 Investigation Report on China Olmesartan Market, 2010-2019
出版日期: 2015年06月04日 內容資訊: 英文 20 Pages
簡介

Olmesartan medoxomil為高血壓治療藥之一,美國在2002年認證、上市,2006年也在中國上市。在中國國內,現在有2億6,600萬名高血壓患者,中國國內主要死因的心臟、腦血管疾病的50%與高血壓有關。高血壓處方藥的市場規模達到9,907億人民幣。因此,Olmesartan的潛在市場規模可說是非常大。

本報告提供中國的Olmesartan的市場相關分析、中國國內的產量及醫院用銷售額、價格趨勢(過去5年份)、各企業、各投藥形態的市場佔有率、未來市場趨勢預測(今後5年份)等調查,並將其結果為您概述為以下內容。

第1章 Olmesartan的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Olmesartan市場概要

  • 專利的現狀與認證情形
  • 主要製造商
  • 市場規模

第3章 Olmesartan的銷售額分析

  • 銷售額(以金額為準)
  • 銷售額(以數量為準)

第4章 主要廠商的市場佔有率分析

  • 市場佔有率(以金額為準)
  • 市場佔有率(以數量為準)

第5章 各劑型的市場規模分析

  • 各劑型的市場佔有率(以金額為準)
  • 各劑型的市場佔有率(以數量為準)

第6章 Olmesartan的醫院用標準價格(各企業)

  • Shanghai Sankyo Pharmaceutical Co., Ltd.
  • Shanghai Sine Promod Pharmaceutical Co., Ltd.
  • Beijing Winsunny Pharmaceutical Co., Ltd.

第7章 主要製造商分析

  • Shanghai Sankyo Pharmaceutical Co., Ltd.
  • Shanghai Sine Promod Pharmaceutical Co., Ltd.
  • Beijing Winsunny Pharmaceutical Co., Ltd.

第8章 中國的Olmesartan市場未來展望

  • 市場規模預測
  • 競爭情形預測

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1506191

Hypertension is the most dangerous factor that leads to the occurrence and resulting death of heart disease, cerebrovascular disease and kidney disease. According to the statistics of WHO, by 2030, nearly 23.6 million around the world will die of cardiovascular disease especially heart disease and apoplexy each year.

With the change of life styles brought about by economic development, the incidence of hypertension keeps growing in China. The number of hypertension patients is estimated to be 266 million with one in five adults suffering from it. Cardia-cerebrovascular disease is the leading cause of death in China and 50% of it relate to hypertension. Therefore, the effective control of hypertension and prevention of cardia-cerebrovascular disease has become an important health concern for health care workers and the public. On the other hand, patients need long-term pharmacotherapy for hypertension is a controllable disease.

In 1991, olmesartan medoxomil was successfully developed by Sankyo Pharmaceuticals Co., Ltd and was patented in many countries. In Apr. 2002, olmesartan medoxomil was approved by FDA to enter the American market in May. It has now become the best-selling drug in the world after it succeeded in the US market.

Compared with other ARBs, olmesartan medoxomil has distinctive pharmacokinetic properties. It develops fast after entering China with annual sales rising from CNY 4448 in 2010 to CNY 99.07 million and CAGR reaching up to 204.15%. Currently, there are three manufacturers of olmesartan in Chinese market: Shanghai Sankyo Pharmaceuticals Co., Ltd, Shanghai Sine Promod Pharmaceutical Co., Ltd and Beijing Winsunny Pharmaceutical Co., Ltd, among which Shanghai Sankyo Pharmaceuticals Co., Ltd has the biggest market share of 94.45% in 2014 with sales value reaching up to CNY 93.57 million in the same year.

With the increase of the incidence of cardiovascular disease and its number of cases, the market size of olmesartan is estimated to keep expanding in the next few years.

Readers can get at least the following information through this report:

  • market size of olmesartan in China
  • major manufacturers of olmesartan in the Chinese market and their market share
  • retail price of olmesartan in China
  • market outlook of olmesartan in China

The author suggests the following groups of people purchase this report:

  • manufacturers of cardiovascular system drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Olmesartan

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Olmesartan in China

  • 2.1. Patent and Approval Status of Olmesartan in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Olmesartan in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Olmesartan in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Olmesartan in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Olmesartan in Chinese Hospitals in 2014

  • 6.1. Shanghai Sankyo Pharmaceuticals Co., Ltd (Trade Name: Benicar)
  • 6.2. Shanghai Sine Promod Pharmaceutical Co., Ltd
  • 6.3. Beijing Winsunny Pharmaceutical Co., Ltd

7. Major Manufacturers of Olmesartan in Chinese Market, 2010-2014

  • 7.1. Shanghai Sankyo Pharmaceuticals Co., Ltd
  • 7.2. Shanghai Sine Promod Pharmaceutical Co., Ltd
  • 7.3. Beijing Winsunny Pharmaceutical Co., Ltd

8. Market Outlook of Olmesartan in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Olmesartan in China
  • Chart Approval Status of Olmesartan in China
  • Chart Sales Status of Olmesartan in China, 2010-2014
  • Chart Sales Value of Olmesartan in China, 2010-2014
  • Chart Sales Value of Olmesartan in Some Regions in China, 2010-2014
  • Chart Sales Volume of Olmesartan in China, 2010-2014
  • Chart Market Size of TOP3 Manufacturers of Olmesartan for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Olmesartan Made by Shanghai Sankyo in China, 2010-2014
  • Chart Sales Value and Market Share of Olmesartan Made by Beijing Winsunny in China, 2010-2014
  • Chart Sales Value and Market Share of Olmesartan Made by Shanghai Sine Promod in China, 2010-2014
  • Chart Sales Value and Market Share of Olmesartan Tablets in China, 2010-2014
  • Chart Price of Olmesartan Made by Shanghai Sankyo Pharmaceuticals Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Olmesartan Made by Shanghai Sine Promod Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Olmesartan Made by Beijing Winsunny Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top